ELMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends June 30
Electromed, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 25, 2026
$27.40−0.02 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $239.32M
- P/E (TTM)
- 21.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
78.5%+2.2 pts over 5 years
Operating margin
18.8%+10.0 pts over 5 years
Net margin
15.3%+8.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +15.3% | +15.4% | +15.6% | +12.4% | |
| Gross profit | +16.0% | +16.6% | +16.2% | +12.5% | |
| Operating income | +43.7% | +51.3% | +34.6% | +16.1% | |
| Net income | +49.9% | +52.8% | +36.8% | +17.7% | |
| EPS, diluted | +52.9% | +53.4% | +36.9% | +17.0% | |
| Free cash flow | -24.4% | – | +24.7% | +17.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 12.3% | 7.5% | 23.3% | |
| Return on assets | 10.2% | 6.7% | 18.8% | |
| Current ratio | 6.38 | 6.83 | 4.69 | |
| Inventory turnover | 2.1× | 3.3× | 4.5× | |
| Capex to revenue | 2.4% | 0.8% | 1.7% | |
| Diluted shares | 8M | 9M | 9M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Electromed generated $32.13M from operations and spent $20.67M on capital expenditure, dividends and share buybacks. 24% of that went back into the business.
Generated
$32.13M
Used
$20.67M
Capital expenditure$4.87M24%Dividends$00%Share buybacks$15.79M76%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin15.3%
×Asset turnover1.23×
×Equity multiplier1.24×
=Return on equity, FY202623.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 15.3% | 1.23× | 1.24× | 23.3% |
| FY2025 | 11.8% | 1.21× | 1.21× | 17.2% |
| FY2024 | 9.4% | 1.12× | 1.19× | 12.5% |
| FY2023 | 6.6% | 1.10× | 1.21× | 8.8% |
| FY2022 | 5.5% | 1.06× | 1.18× | 6.9% |
| FY2021 | 6.6% | 1.02× | 1.12× | 7.5% |
| FY2020 | 12.8% | 1.04× | 1.12× | 14.9% |
| FY2019 | 6.3% | 1.10× | 1.18× | 8.2% |
| FY2018 | 6.5% | 1.12× | 1.19× | 8.6% |
| FY2017 | 8.6% | 1.19× | 1.21× | 12.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
7of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$11.30M
- Cash generatingOperating cash flow above zero$9.67M
- Return on assets improvedROA up on the prior year14.4% → 21.0%
- Earnings backed by cashOperating cash flow above net income$9.67M vs $11.30M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.31 → 4.69
- No dilutionShare count did not rise9M → 9M
- Gross margin improvedGross margin up on the prior year78.08% → 78.54%
- More efficientAsset turnover rose1.23 → 1.37